JPRN-jRCTs021180021招募中2 期
pfront abiraterone and docetaxel in patients with high-risk metastatic hormone naive prostate cancer - UFAD in mHNPC
arita Shintaro0 个研究点目标入组 100 人开始时间: 2019年3月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Patients who meet the criteria as described below will be included:
- •1.Historically confirmed prostate cancer
- •2.Metastatic disease on radiographic examinations without any initial treatment
- •3.20 years and older
- •4.ECOG performance status 0-2
- •5.Plan to receive androgen-deprivation therapy including leuteinizing hormone-releasing hormone (LHRH) agonist, LHRH antagonist, surgical castration with and without bicalutamide
- •6.Sufficient function of main organ and normal hematopoietic function, normal liver function and normal renal function filled the following
- •*Leukocyte counts >= 3,000/mm3
- •*N*Platelets >= 750,000/mm3
- •*Hemoglobin concentration >= 9.0 g/dL
- •*AST <= 90IU
- •*ALT <= 100IU
- •*Total bilirubin <=2.0mg/dL.
- •*Serum creatinine, <= 3.0mg/dL
- •7. Agree with the protocol with signed informed consent
排除标准
- •Patients who meet the criteria below will be excluded:
- •1.Severe cardiovascular disease and diabetes mellitus
- •2.Chronic pulmonary disease
- •3.Allergy to taxanes
- •4. Active concomitant malignancy
- •5. Difficulty of understanding of the trial because of mental disease
- •6.Inappropriate patients for this study judged by the physicians
研究者
相似试验
尚未招募
2 期
To study whether maintenance treatment with Abiraterone after docetaxel chemotherapy leads to further improvement in metastatic hormone sensitive prostate cancer.CTRI/2020/02/023447Tata Memorial Centre
招募中
3 期
The study of compairing benefit of Abiraterone low versus full dose with Docetaxel in Prostate CancerCTRI/2023/03/050180Tata Memorial Hospital
已完成
不适用
pfront abiraterone and docetaxel administration in patients with high-risk metastatic hormone-naive prostate cancerMetastatic prostate cancer without initial treatmentJPRN-UMIN000021079Department of Urology, Akita University School of Medicine301
招募中
2 期
The effect of addition of low dose abiraterone to the ADT+RT in local recurrent prostate cancersProstate cancer.Malignant neoplasm of prostateIRCT20120618010057N2Shahid Beheshti University of Medical Sciences64
进行中（未招募）
1 期
Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers.EUCTR2014-001274-34-ITFondazione IRCCS Istituto Nazionale dei Tumori24